Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Oncodesign and Banook Central Imaging Sign a Collaboration Agreement

Published: Tuesday, September 10, 2013
Last Updated: Monday, September 09, 2013
Bookmark and Share
The global reaching partnership aims to provide clinical researchers with new biomarkers and validated image analysis protocols, ensuring a continuum from preclinical to clinical phase in the development of anticancer therapies.

Oncodesign and Banook Central Imaging have announced the start of a partnership to expand the use of new approaches in pharmaco-imaging.

The partners expect to share expertise, co-promote joint activities and jointly engage in scientific collaboration to standardize image acquisition and analysis protocols in early clinical phases.

The financial details of the agreement were not disclosed.

The various medical imaging procedures (computed tomography, magnetic resonance imaging, positron emission tomography, single-photon emission computed tomography and ultrasound imaging) have become indispensable tools in early-stage development of anticancer compounds.

The information they provide about the disease and the effects of molecules is highly valuable in identifying translational markers in preclinical and clinical phases.

The partnership between Oncodesign and Banook Central Imaging breaks new ground in the evaluation of anticancer therapies by helping to guide a compound from research laboratory to patient through the pursuit of greater consistency in the imaging protocols used during the development cycle, in accordance with good clinical practice.

The first phase of this partnership will last three years. First results are expected by early 2014.

“Oncodesign leads the way in pharmaco-imaging. As well as conducting preclinical proofs of concept, we have a long tradition of striving to provide our clients with tools for improving the characterization of their molecule's therapeutic potential, to expedite clinical trials in humans,” said Philippe Genne, PhD, CEO and founder of Oncodesign.

Genne continued, “In the coming weeks, our partnership with Banook Central Imaging will help us to provide our clients with practical solutions, ensuring that the measure of efficacy of anticancer therapies is attainable from one phase of development to the next.”

“It is crucial that the challenges of standardizing biomarkers in pharmaco-imaging are considered from the early phases of clinical development,” said Dr Pascal Voiriot, MSc, chairman of Banook Central Imaging.

Dr Voiriot continued, “Our partnership with Oncodesign is in line with our strategy which aims to implement relevant biomarkers in medical imaging, focusing ultimately on personalized medicine and the ability to produce a considerable time saving for the direct benefit of research laboratories and patients.”

A joint announcement about the partnership will be made at the ESMO (European Society for Medical Oncology) conference to be held in Amsterdam, the Netherlands, from September 27 to October 1.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oncodesign Enters into a Services Agreement with Eisai
The program aims to identify useful patient stratification biomarkers for Eisai’s Halaven® eribulin using patient-derived xenograft models.
Friday, December 26, 2014
Oncodesign and OSEO Announce Funding of EUR 13.4 Million
This private-public partnership project, which aims to put in place the first national subsidiary dedicated to personalized medicine in oncology, has a EUR 41 million overall investment budget.
Tuesday, March 12, 2013
Scientific News
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
New Gene Map Reveals Cancer’s Achilles’ Heel
Team of researchers switches off almost 18,000 genes
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos